Early-phase [F-18]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury
Leonie Beyer, Alexander Nitschmann, Henryk Barthel, Thilo van Eimeren, Marcus Unterrainer, Julia Sauerbeck, Ken Marek, Mengmeng Song, Carla Palleis, Gesine Respondek, Jochen Hammes, Michael T Barbe, Oezguer Onur, Frank Jessen, Dorothee Saur, Matthias L Schroeter, Jost-Julian Rumpf, Michael Rullmann, Andreas Schildan, Marianne Patt Show all
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2020
PURPOSE: Second-generation tau radiotracers for use with positron emission tomography (PET) have been developed for visualization of tau deposits in vivo. For several β-amyloid and first-generation tau-PET radiotracers, it has been shown that early-phase images can be used as a surrogate of neuronal injury. Therefore, we investigated the performance of early acquisitions of the novel tau-PET radiotracer [18F]PI-2620 as a potential substitute for [18F]fluorodeoxyglucose ([18F]FDG). METHODS: Twenty-six subjects were referred with suspected tauopathies or overlapping parkinsonian syndromes (Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome, multi-system atrophy, Parkins..View full abstract
Awarded by Deutsche Forschungsgemeinschaft (DFG) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy)
Awarded by German Federal Ministry of Education and Research (BMBF)
Open Access funding provided by Projekt DEAL. C.P. received research funding from Luneburg heritage. M.T.B. received research funding from the Felgenhauer-Stiftung, Forschungspool Klinische Studien (University of Cologne), H2020, Medtronic and Boston Scientific. G. U. H was funded by the Deutsche Forschungsgemeinschaft (DFG) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy-ID 390857198), the German Federal Ministry of Education and Research (BMBF, 01EK1605A HitTau), the NOMIS foundation (FTLD project). and received research support from GE Healthcare and Neuropore.